Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720537 | 0.85 | HTR1A (0.36) | OPRM1 | |
| SCHEMBL4720742 | 0.71 | SLC6A3 (0.36) | LMNA | |
| SCHEMBL15043601 | 0.62 | OPRM1 (0.42) | OPRM1 | |
| SCHEMBL8362857 | 0.62 | SLC6A3 (0.37) | BACE1CACNA1HLMNA | |
| SCHEMBL15043683 | 0.61 | SLC6A4 (0.40) | OPRM1 | |
| SCHEMBL2175183 | 0.59 | SLC6A3 (0.40) | OPRM1 | |
| SCHEMBL29002712 | 0.59 | IDO1 (0.40) | LMNA | |
| SCHEMBL12614285 | 0.59 | SLC6A3 (0.45) | OPRM1 | |
| SCHEMBL5494541 | 0.58 | OPRM1 (0.36) | OPRM1 | |
| SCHEMBL9604744 | 0.58 | SLC6A3 (0.35) | BACE1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035199-A9 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-20110034500-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-02-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | BACE1 4036/4885OPRM1 10/4885CACNA1H 52/4885 |
| US-20110034500-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | SCN3A, SCN1B, SCN2B | BACE1 3006/4885OPRM1 210/4885CACNA1H 77/4885 |
| US-20120035199-A9 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | SCN3A, SCN1B, SCN2B | BACE1 3006/4885OPRM1 210/4885CACNA1H 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.